CA-ARYAKA
23.3.2021 13:02:07 CET | Business Wire | Press release
Aryaka® , the leader in fully managed Cloud-First WAN solutions, today published its fifth annual 2021 State of the WAN report, the industry’s foremost survey into global SD-WAN and SASE planning. Key trends identified in this year’s report include:
- Accelerating fusion of networking and security planning, with almost a third of enterprises stating that they are already deploying what they consider to be a secure access service edge (SASE) architecture
- A hybrid work environment that will persist after the pandemic recedes, with over 80% stating that they expect over a quarter of workers to remain remote, and over two-thirds desiring flexibility between on-premises and remote deployments
- Continued WAN and application growth, resulting in increased network complexity. The number of enterprises reporting they’re deploying over 500 distinct applications has grown to 46%. 37% of enterprises identify complexity as their number one network concern
- 43% of enterprises identify application performance as an underlying driver for WAN transformation. However, WAN transformations have slowed this year due to the pandemic
- Over 70% of enterprises intend to move to managed services versus just 18% who prefer the autonomy of a do-it-yourself WAN solution
"Every year I look forward to Aryaka's high quality State of the WAN report for information on industry trends,” said Scott Raynovich, founder and chief analyst at Futuriom. “This year, the report reflects many of the same trends we are seeing at Futuriom, which include the ongoing integration of cloud-based networking services and security -- otherwise known as Secure Access Service Edge (SASE) -- as well as strong demand for virtualized networking solutions targeted at Work from Anywhere (WFA) and hybrid work environments. It's a good read!”
Year-on-Year Trends with Changing Challenges and Priorities
The WAN continues to extend its reach, with the number of enterprises connecting to over 100 inter-regional sites growing by 50%, from 19% in 2020 to 28% in 2021. This is coupled with continued application growth, with the number of enterprises stating that they’ve deployed over 500 distinct applications growing to 46%, compared to 32% in 2021. As evidence of collaboration traction, Zoom was identified as critical by 36% in 2021, up from 25% in 2020.
One finding that did not noticeably change year-on-year is complexity, which was identified by 36% of enterprises as their number one network issue. Interestingly, those who identified cost as a major issue grew to 20% in 2021 from 16% in 2020, a 25% increase. This may be attributed to cloud or MPLS cost concerns.
Overall, investment priorities did see recede in some areas, due to tactical pandemic concerns driving near-term planning. For example, only 17% of respondents plan to conduct an SD-WAN/SASE-driven network refresh this year versus 29% in 2020. However, combining this with remote access upgrades, a new entry at 22%, and security, at 21%, results in strong momentum going into 2021. In contrast, LTE/5G experienced growth from 24% in 2020 to 31% in 2021. Finally, VPN investment is at 31% this year versus 27% in 2020. Aryaka believes the new remote workforce, due to the pandemic, led to this VPN increase.
For actual deployment, managed services still reign supreme at 71%, versus 18% who are looking for a do-it-yourself (DIY) solution. Many enterprises are also further along the deployment lifecycle, with 26% evaluating SD-WAN this year, up from 22% in 2020. This increasing market maturity is reflected in a drop in identified barriers to SD-WAN adoption. Enterprises are less concerned that the WAN service won’t address application performance, coming in at 36% this year, versus 43% in 2020, with corresponding drops in SLA concerns, technology maturity, and lack of skills.
A Closer Look at SASE and the Rise of the Hybrid Workplace
Enterprise SASE deployment plans are accelerating, with 29% stating that they are already deploying what they consider to be a SASE architecture. Another 56% are planning to deploy a SASE architecture in the next 12-24 months. As part of a complete SASE architecture, the top capability identified was SD-WAN transport at 34%. And for deployment, over half state that they prefer a solution that includes technology from both their WAN vendor and security specialists, spanning across cloud and the edge.
When the pandemic hit, workers around the world migrated from their offices to their homes, a shift that will also impact future planning and investment throughout 2021. More than half (59%) of the respondents stated they expect 25-50% of their workers to remain remote, while 21% say they are planning for more than 50% of their workforce to continue working from home. Businesses are also prioritizing flexibility, with 63% stating that they consider the ability to quickly move resources between on-premises and remote to be very important.
“The fifth edition of the Global State of the WAN is bigger and better than ever, with survey inputs and insights from over 1350 Enterprises worldwide,” said Shashi Kiran, CMO of Aryaka. “On behalf of Aryaka Networks, I would like to express my gratitude to those who participated in this survey, and hope this serves as an excellent resource and guidebook for all those CIOs, network, cloud and security practitioners to leverage and proactively Plan their WAN™. Of particular interest are the trends focusing on SD-WAN and SASE deployments.”
Study Methodology
The Fifth Annual Global Aryaka 2021 State of the WAN study surveyed over 1350 global IT and network practitioners at enterprises spanning all verticals, headquartered in NA, APAC and EMEA. The survey asked respondents about their networking and performance challenges, priorities and their plans for 2021 and beyond.
Aryaka to Host 2021 The State of the WAN Webinars
Join us at the following dates/times for a lively panel discussion on the “Aryaka 2021 Global State of the WAN.” Regional observations will also be presented:
● North America |
March 23, 1pm EST, 10am PST |
|
● EMEA |
March 23, 3pm GMT |
|
● APAC |
March 24, 930am IST, Noon Beijing |
This interactive format allows the panel of experts to deep dive into the Fifth annual State of the WAN report, which will include further analysis of the key findings driving digital transformation.
Download Report Here
:
https://www.aryaka.com/state-of-wan-2021/
Download Infographic Here
:
https://www.aryaka.com/docs/aryaka-state-of-the-wan-2021-infographic.pdf
Additional Resources:
- Aryaka Managed SD-WAN as-a-Service . This datasheet explains how the Aryaka SmartServices platform is built for the Cloud-First world. Specifically, this means there are no products to buy, and no inventory, deployment hassles, patches or configurations to worry about.
- Aryaka’s Cloud-First WAN for Dummies . This e-book explains everything you need to know about consuming your network as-a-Service, how to achieve fully integrated security, and how to make your network as easy as your cloud.
For more on Aryaka, please visit: https://www.aryaka.com/
Visit the Aryaka blog: https://www.aryaka.com/blog/
Follow Aryaka on Twitter: @AryakaNetworks
Visit Aryaka on LinkedIn: https://www.linkedin.com/company/aryaka-networks/
About Aryaka
Aryaka, the Cloud-First WAN company, brings agility, simplicity and a great experience to consuming the WAN-as-a-service for network and security. The company provides an optimized global network and innovative technology stack, delivering the industry’s #1 managed SD-WAN service and setting the gold standard for application performance. Aryaka’s SmartServices platform offers connectivity, application acceleration, security, cloud networking and insights that leverage global orchestration and provisioning. The company’s customers include hundreds of global enterprises including several in the Fortune 100.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005451/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
